Literature DB >> 28083886

Incidence and risk estimate of drug-induced agranulocytosis in Hong Kong Chinese. A population-based case-control study.

Chor-Wing Sing1, Ian C K Wong2,3,4, Bernard M Y Cheung4,5, Johnny C Y Chan5, Jody K P Chu1, Ching-Lung Cheung1,4,5.   

Abstract

PURPOSE: Drug-induced agranulocytosis is a rare but life-threatening adverse drug reaction. Its epidemiology in Chinese is largely unknown. This study aimed to estimate the incidence, mortality, and risk of the drugs associated with agranulocytosis in Hong Kong Chinese.
METHODS: A population-based case-control study was conducted using the Clinical Data Analysis and Reporting System, a database managed by the Hong Kong Hospital Authority. Patients with drug-induced agranulocytosis from 1 January 2004 to 31 December 2013 were identified. World Health Organization causality assessment was used to evaluate the possible drug aetiology of each case. Odd ratios (ORs) of the drug exposure were calculated using exact conditional logistic regression.
RESULTS: A total of 155 cases of drug-induced agranulocytosis were identified. Mean age was 51.4 years, and 95 cases were female. Incidence rate was estimated to be 2.2 cases per million person-years, and the all-cause mortality of patients with drug-induced agranulocytosis was 3.9%. Among the cases, the most common associated drug groups were antithyroid drugs (41.9%), antimicrobials (20%), anticonvulsants (10.3%), and antipsychotics (6.5%). Carbimazole had the highest risk of agranulocytosis (adjusted OR 416.7, 95% confidence interval (CI) 51.5-3372.9) with an incidence of 9.2 (95%CI 6.9-12.1) per 10 000 users and 3.6 (95%CI 2.7-4.8) per 10 000 user-years. Other drugs with significant risk included cephalosporins, clozapine, penicillins, phenytoin, and propyl thiouracil.
CONCLUSIONS: The incidence and mortality in Hong Kong Chinese were relatively low compared to Caucasians. Antithyroid drugs were the most common implicated drug class, and carbimazole had the highest risk of agranulocytosis.
Copyright © 2017 John Wiley & Sons, Ltd. Copyright © 2017 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Chinese; adverse drug reaction; agranulocytosis; pharmacoepidemiology

Mesh:

Year:  2017        PMID: 28083886     DOI: 10.1002/pds.4156

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  6 in total

Review 1.  Hematopoiesis and the bacterial microbiome.

Authors:  Hannah Yan; Megan T Baldridge; Katherine Y King
Journal:  Blood       Date:  2018-05-31       Impact factor: 22.113

2.  Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program.

Authors:  Eric P Borrelli; Erica Y Lee; Aisling R Caffrey
Journal:  Ment Health Clin       Date:  2020-05-07

3.  Vancomycin-associated acute kidney injury in Hong Kong in 2012-2016.

Authors:  Xuzhen Qin; Man-Fung Tsoi; Xinyu Zhao; Lin Zhang; Zhihong Qi; Bernard M Y Cheung
Journal:  BMC Nephrol       Date:  2020-02-03       Impact factor: 2.388

4.  COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study.

Authors:  Chor-Wing Sing; Casey Tze Lam Tang; Celine Sze Ling Chui; Min Fan; Francisco Tsz Tsun Lai; Xue Li; Eric Yuk Fai Wan; Carlos King Ho Wong; Esther Wai Yin Chan; Ivan Fan Ngai Hung; Anskar Yu-Hung Leung; Ching-Lung Cheung; Ian Chi Kei Wong
Journal:  Am J Hematol       Date:  2022-02-09       Impact factor: 10.047

5.  The Co-Existence of Agranulocytosis and Stevens-Johnson Syndrome (SJS) in Carbamazepine Therapy: A Case Report.

Authors:  Saima Batool; Diana Voloshyna; Muhammad Usama; Muhammad Suleman; Qudsia I Sandhu; Laxman Nepal; Naglaa G Ghobriel; Jaina Mengar; Ahmed Soodod Mohammed Rasmy
Journal:  Cureus       Date:  2022-09-07

6.  Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.

Authors:  J Boegeholz; C S Brueggen; C Pauli; F Dimitriou; E Haralambieva; R Dummer; M G Manz; C C Widmer
Journal:  BMC Cancer       Date:  2020-04-14       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.